Related Experiment Video
Updated: Aug 6, 2025
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Use of mesenchymal stem cell therapy in COVID-19 related strokes
Mahika Rawat1, Chiao Ng1, Emaad Khan1
1Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA.
Insights
Mesenchymal stem cell therapy shows promise for treating COVID-19 and related strokes. This immunotherapy offers regenerative and anti-inflammatory benefits, potentially aiding recovery and mitigating stroke risks in COVID-19 patients.
Area of Science:
- Immunotherapy and Regenerative Medicine
- Infectious Diseases and Neurology
Background:
- Coronavirus disease 2019 (COVID-19) disproportionately affects males and minority groups.
- COVID-19 increases the risk of ischemic strokes due to elevated cytokines and clotting factors.
- Current COVID-19 treatments include antivirals and monoclonal antibodies.
Purpose of the Study:
- To review the incidence of COVID-19 and associated stroke cases.
- To evaluate mesenchymal stem cells (MSCs) and MSC-derived exosomes as potential immunotherapies for COVID-19.
- To discuss the dual therapeutic potential of MSCs for COVID-19 and COVID-19-induced strokes.
Main Methods:
- Literature review of COVID-19, stroke incidence, and mesenchymal stem cell therapies.
- Analysis of the regenerative, anti-inflammatory, and immunomodulatory properties of MSCs.
- Exploration of MSC-based treatments for COVID-19 and ischemic stroke.
Main Results:
- Mesenchymal stem cell therapy demonstrates regenerative, anti-inflammatory, and immunomodulatory effects beneficial for COVID-19 recovery.
- COVID-19 patients face an increased risk of ischemic strokes.
- MSCs and their exosomes may offer a dual therapeutic approach for COVID-19 and associated strokes.
Conclusions:
- Mesenchymal stem cells and MSC-derived exosomes represent promising immunotherapeutic options for COVID-19.
- These therapies could potentially mitigate the increased stroke risk in COVID-19 patients.
- Further evaluation of MSC-based treatments is warranted for COVID-19 and related neurological complications.
Abstract:
Coronavirus disease 2019 (COVID-19) has affected a broad demographics, eliciting a more significant effect on specific groups such as males, African Americans, and Hispanic minorities. Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies. However, immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19. Mesenchymal stem cell therapy offers regenerative, anti-inflammatory, and immunomodulatory properties that can speed up the recovery from COVID-19. Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes, as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors. Most stroke cases that occur in COVID-19 patients are ischemic strokes. Therefore, with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes, COVID-19-induced stroke patients might benefit from dual-ended treatment. The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.
More Related Videos
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
10:03Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model
Published on: November 21, 2019
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...